JP2024513313A5 - - Google Patents
Info
- Publication number
- JP2024513313A5 JP2024513313A5 JP2023554307A JP2023554307A JP2024513313A5 JP 2024513313 A5 JP2024513313 A5 JP 2024513313A5 JP 2023554307 A JP2023554307 A JP 2023554307A JP 2023554307 A JP2023554307 A JP 2023554307A JP 2024513313 A5 JP2024513313 A5 JP 2024513313A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- fragment
- antibody
- fab
- binding fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163158205P | 2021-03-08 | 2021-03-08 | |
| US63/158,205 | 2021-03-08 | ||
| PCT/US2022/019375 WO2022192281A1 (en) | 2021-03-08 | 2022-03-08 | MOLECULES THAT BIND TO CD66e POLYPEPTIDES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513313A JP2024513313A (ja) | 2024-03-25 |
| JP2024513313A5 true JP2024513313A5 (https=) | 2025-02-05 |
Family
ID=83228255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023554307A Pending JP2024513313A (ja) | 2021-03-08 | 2022-03-08 | ＣＤ６６ｅポリペプチドに結合する分子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240166760A1 (https=) |
| EP (1) | EP4305069A4 (https=) |
| JP (1) | JP2024513313A (https=) |
| AU (1) | AU2022233150A1 (https=) |
| CA (1) | CA3212830A1 (https=) |
| WO (1) | WO2022192281A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4608874A2 (en) * | 2022-10-28 | 2025-09-03 | Memorial Sloan Kettering Cancer Center | Anti-adam10 antibodies and uses in treatment of cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME00502B (me) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| WO2004050850A2 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
| EP2478110B1 (en) * | 2009-09-16 | 2016-01-06 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| DK3199552T3 (da) * | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| WO2019204827A2 (en) * | 2018-04-20 | 2019-10-24 | The Regents Of The University Of California | Treatment of prostate cancer using chimeric antigen receptors |
| AU2020289301B2 (en) * | 2019-06-04 | 2025-07-24 | Biotheus Inc. | CEACAM5-resistant monoclonal antibody and preparation method thereof and use thereof |
| AU2020288829A1 (en) * | 2019-06-04 | 2021-12-02 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered T cells for immunotherapy |
-
2022
- 2022-03-08 US US18/281,157 patent/US20240166760A1/en active Pending
- 2022-03-08 JP JP2023554307A patent/JP2024513313A/ja active Pending
- 2022-03-08 EP EP22767820.8A patent/EP4305069A4/en active Pending
- 2022-03-08 AU AU2022233150A patent/AU2022233150A1/en active Pending
- 2022-03-08 CA CA3212830A patent/CA3212830A1/en active Pending
- 2022-03-08 WO PCT/US2022/019375 patent/WO2022192281A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| NZ599497A (en) | Humanized antibodies to amyloid beta | |
| NZ623706A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| NZ585559A (en) | Humanized antibodies against tl1a | |
| IL299221A (en) | Cd3 binding antibodies | |
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav | |
| JP2021514973A5 (https=) | ||
| ATE452147T1 (de) | Antikörper mit korrigierten cdr | |
| CY1118709T1 (el) | Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf | |
| JP2024156657A5 (https=) | ||
| JP2017505125A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ599683A (en) | Anti-ilt7 antibody | |
| NZ596042A (en) | Humanized anti-factor d antibodies | |
| WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| JP2011526249A5 (https=) | ||
| AR078796A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| RU2018106456A (ru) | Антитело к epha4 | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. |